Yasir Y. Elamin

The University of Texas MD Anderson Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 19 papers. Top paper: “Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC”.

Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.04.026

N/A

6.8DataRank · unranked

195 citations

Marcelo V. Negrão, Seyedeh Dibaj, Runzhe Chen, Alexandre Reuben, Jadi M. Bohac +32 more

Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial

The Lancet(2023)10.1016/s0140-6736(23)01384-3

N/A

5.0DataRank · unranked

230 citations

Steven H. Lin, Wenli Dong, Zhongxing Liao, Saumil Gandhi, Carl M. Gay +23 more

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

New England Journal of Medicine(2023)10.1056/nejmoa2309457

N/A

4.6DataRank · unranked

218 citations

Benjamin Solomon, Herbert H. Loong, Keunchil Park, M. Pérol, Edurne Arriola +19 more

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Nature Medicine(2023)10.1038/s41591-022-02189-0

N/A

4.1DataRank · unranked

213 citations

Cheuk Hong Leung, Annikka Weissferdt, Apar Pataer, Brett W. Carter, Myrna C. B. Godoy +52 more

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

Cancer Cell(2022)10.1016/j.ccell.2022.06.006

N/A

3.9DataRank · unranked

106 citations

Jacqulyne Robichaux, Brett W. Carter, Mehmet Altan, Hai T. Tran, Don L. Gibbons +22 more

Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance

Nature Medicine(2023)10.1038/s41591-023-02371-y

N/A

0.933DataRank · unranked

501 citations

Enyu Dai, Yating Li, Guangchun Han, Guangsheng Pei, Davis R. Ingram +39 more

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Nature(2021)10.1038/s41586-021-03898-1

N/A

0.922DataRank · unranked

467 citations

Xiuning Le, R. S. K. Vijayan, J. Kevin Hicks, Simon Heeke, Yasir Y. Elamin +28 more

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002891

N/A

0.854DataRank · unranked

296 citations

Ferdinandos Skoulidis, Meagan Montesion, Katja Schulze, Ilze Bāra, Vincent K. Shen +33 more

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Nature(2024)10.1038/s41586-024-07943-7

N/A

0.769DataRank · unranked

168 citations

Haniel A. Araújo, Minh Truong, Yu Qian, Xin Sun, Ana Galán‐Cobo +95 more

Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.12.010

N/A

0.727DataRank · unranked

126 citations

Marcelo V. Negrão, Alexandre Reuben, Lorenzo Federico, Lixia Diao, Daniel J. McGrail +34 more

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

The Lancet Digital Health(2023)10.1016/s2589-7500(23)00082-1

N/A

0.708DataRank · unranked

111 citations

Lingzhi Hong, Muhammad Aminu, Natalie I. Vokes, Pingjun Chen, Morteza Salehjahromi +44 more

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance

Cancer Cell(2023)10.1016/j.ccell.2023.01.007

N/A

0.700DataRank · unranked

105 citations

Yan Yang, Simon Heeke, Sonia Patel, Alissa Poteete, Hibiki Udagawa +22 more

Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights

Nature Communications(2024)10.1038/s41467-024-47512-0

N/A

0.672DataRank · unranked

87 citations

Muhammad Aminu, Tatiana V. Karpinets, Pingjun Chen, Maliazurina B. Saad, Morteza Salehjahromi +32 more

Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.11.022

N/A

0.646DataRank · unranked

73 citations

Jacqulyne Robichaux, Matthew H. Herynk, Tina Cascone, Xiuning Le, Yasir Y. Elamin +17 more

Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets

JTO Clinical and Research Reports(2023)10.1016/j.jtocrr.2023.100623

N/A

0.504DataRank · unranked

12 citations

Whitney E. Lewis, C. Allison Stewart, Benjamin B. Morris, Luisa M. Solis, Alejandra G. Serrano +31 more

Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.07.121

N/A

0.373DataRank · unranked

11 citations

Alessandro Di Federico, Bolun Liu, Alissa J. Cooper, Joao V. Alessi, Phoebe Clark +25 more

Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity

Nature Communications(2025)10.1038/s41467-025-61817-8

N/A

0.345DataRank · unranked

9 citations

Jacqulyne Robichaux, Monique B. Nilsson, R. S. K. Vijayan, Ashwin Ravichandran, Jia Wu +21 more

Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC

Nature Communications(2025)10.1038/s41467-025-61823-w

N/A

0.312DataRank · unranked

7 citations

Qasem Al-Tashi, Lingzhi Hong, Vivek Verma, Wentao Li, Daniel Boiarsky +32 more

Predictive biomarkers of benefit to axitinib plus avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.6096

N/A

0DataRank · unranked

0 citations

Daniel J. McGrail, Simon Heeke, Luana Guimarães de Sousa, Kaiyi Li, Diana Bell +8 more